Maiwei Bio (688062.SH): The application for market approval of the injection 9MW0813 has been accepted.

Wisdom Finance and Economics APP news, Mevbi Biological (688062.SH) announced that recently, the company received the "Acceptance Notice" approved and issued by the National Medical Products Administration, and the application for market approval of 9MW0813 injection has been accepted. It is used for the treatment of diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD).